Money, Life And Pursuit Of Paxlovid: Behind China's Mania For Pfizer COVID Drug
Will New Approval Relieve Short Supplies?
From being little known to sought after by millions, Pfizer’s oral antiviral Paxlovid is fast becoming the most pursued medicine in China, amid the largest outbreak of COVID-19 infections the world has yet seen.
You may also be interested in...
Six months after Brii obtained Chinese approval for its antibody combo for COVID-19, the Beijing joint venture finally launches the drug in China.
The hard going could get even tougher as a funding crunch continues for China’s biotech sector, which is being hit by a paradox that could see more pain ahead, leading investors to take the pulse of the sector as the Year of the Rabbit starts.
From orphan to cancer drugs, more products have had their prices cut in the latest round of reimbursement negotiations in China. Although the 60% average across 100 medicines was considered mild given it didn’t go beyond the previous year, it was still chilling and is prompting more firms, both multinational and domestic, to walk away from the process.